| Characteristic | Overall N = 1481 |
Proglide N = 1061 |
Manta N = 421 |
p-value2 |
|---|---|---|---|---|
| Sex | 0.464 | |||
| Female | 88 (59%) | 65 (61%) | 23 (55%) | |
| Male | 60 (41%) | 41 (39%) | 19 (45%) | |
| Age (years) | 80.6 (5.3) | 80.2 (5.7) | 81.5 (4.1) | 0.271 |
| Hypertension | 125 (84%) | 87 (82%) | 38 (90%) | 0.203 |
| Diabetes | 55 (37%) | 37 (35%) | 18 (43%) | 0.367 |
| Dyslipidemia | 93 (63%) | 65 (61%) | 28 (67%) | 0.544 |
| Smoking | <0.001 | |||
| Actual Smoker | 10 (6.8%) | 9 (8.6%) | 1 (2.4%) | |
| Former Smoker | 26 (18%) | 25 (24%) | 1 (2.4%) | |
| No | 111 (76%) | 71 (68%) | 40 (95%) | |
| Family History of CV Disease | 12 (8.1%) | 10 (9.4%) | 2 (4.8%) | 0.510 |
| Lone AF | 3 (2.0%) | 3 (2.8%) | 0 (0%) | 0.558 |
| Recurrent Paroxysmal AF | 9 (6.1%) | 7 (6.6%) | 2 (4.8%) | >0.999 |
| Recurrent Persistent AF | 4 (2.7%) | 3 (2.8%) | 1 (2.4%) | >0.999 |
| Permanent AF | 21 (14%) | 14 (13%) | 7 (17%) | 0.587 |
| Cirrhosis | 1 (0.7%) | 1 (0.9%) | 0 (0%) | >0.999 |
| Chronic Kidney Disease | 35 (24%) | 25 (24%) | 10 (24%) | 0.977 |
| Dialysis | 1 (0.7%) | 1 (1.0%) | 0 (0%) | >0.999 |
| COPD | 23 (16%) | 16 (15%) | 7 (17%) | 0.812 |
| Neurological Dysfunction | 12 (8.1%) | 8 (7.5%) | 4 (9.5%) | 0.742 |
| Porcelain Aorta | ||||
| 0 | 148 (100%) | 106 (100%) | 42 (100%) | |
| Peripheral Arterial Disease | 11 (7.4%) | 7 (6.6%) | 4 (9.5%) | 0.508 |
| Prior Ulcers | 2 (1.4%) | 1 (0.9%) | 1 (2.4%) | 0.488 |
| Malignancy | 6 (4.1%) | 5 (4.7%) | 1 (2.4%) | 0.675 |
| Critical Preoperative State | 1 (0.7%) | 0 (0%) | 1 (2.4%) | 0.284 |
| Comorbidities | 62 (42%) | 40 (38%) | 22 (52%) | 0.104 |
| Prior Cardiac Surgery (non-CABG) | 8 (5.4%) | 7 (6.6%) | 1 (2.4%) | 0.441 |
| Pre-TAVI Balloon Valvuloplasty | ||||
| 0 | 148 (100%) | 106 (100%) | 42 (100%) | |
| Prior TAVI | 1 (0.7%) | 1 (0.9%) | 0 (0%) | >0.999 |
| Prior Cardiac Surgery | 13 (8.8%) | 11 (10%) | 2 (4.8%) | 0.351 |
| Prior CABG | 4 (2.7%) | 3 (2.8%) | 1 (2.4%) | >0.999 |
| Prior SAVR | 10 (6.8%) | 9 (8.5%) | 1 (2.4%) | 0.283 |
| Prosthesis Type | 10 (6.8%) | 9 (8.5%) | 1 (2.4%) | 0.283 |
| Prior PCI | 25 (17%) | 18 (17%) | 7 (17%) | 0.963 |
| Prior MI | 19 (13%) | 17 (16%) | 2 (4.8%) | 0.064 |
| Prior TIA | 3 (2.0%) | 1 (0.9%) | 2 (4.8%) | 0.194 |
| Prior Stroke | 8 (5.4%) | 5 (4.7%) | 3 (7.1%) | 0.688 |
| Prior Pacemaker | 11 (7.4%) | 5 (4.7%) | 6 (14%) | 0.076 |
| Heart Failure Hospitalizations | 20 (14%) | 12 (11%) | 8 (19%) | 0.215 |
| CCS Angina Class | 0.131 | |||
| 0 | 113 (76%) | 76 (72%) | 37 (88%) | |
| 1 | 21 (14%) | 18 (17%) | 3 (7.1%) | |
| 2 | 14 (9.5%) | 12 (11%) | 2 (4.8%) | |
| Syncope | 13 (8.8%) | 7 (6.6%) | 6 (14%) | 0.194 |
| Angina | 0.246 | |||
| 0 | 112 (76%) | 76 (72%) | 36 (86%) | |
| 1 | 29 (20%) | 24 (23%) | 5 (12%) | |
| 2 | 7 (4.7%) | 6 (5.7%) | 1 (2.4%) | |
| Dyspnea | 0.350 | |||
| 0 | 13 (8.8%) | 7 (6.6%) | 6 (14%) | |
| 1 | 45 (30%) | 31 (29%) | 14 (33%) | |
| 2 | 56 (38%) | 41 (39%) | 15 (36%) | |
| 3 | 34 (23%) | 27 (25%) | 7 (17%) | |
| NYHA Class | 0.896 | |||
| II | 67 (45%) | 47 (44%) | 20 (48%) | |
| III | 80 (54%) | 58 (55%) | 22 (52%) | |
| IV | 1 (0.7%) | 1 (0.9%) | 0 (0%) | |
| Weight (kg) | 71 (14) | 69 (12) | 80 (18) | 0.066 |
| Height (cm) | 1.58 (0.09) | 1.57 (0.09) | 1.61 (0.10) | 0.375 |
| BMI (kg/m²) | 28.1 (4.9) | 27.4 (4.6) | 31.2 (5.3) | 0.036 |
| Heart Failure | 1.71 (0.18) | 1.68 (0.16) | 1.85 (0.24) | 0.069 |
| ARBs | 67 (45%) | 49 (46%) | 18 (43%) | 0.710 |
| ACE Inhibitors | 33 (22%) | 24 (23%) | 9 (21%) | 0.873 |
| Nitrates | 7 (4.7%) | 5 (4.7%) | 2 (4.8%) | >0.999 |
| Amiodarone | 3 (2.0%) | 2 (1.9%) | 1 (2.4%) | >0.999 |
| Digitalis | 2 (1.4%) | 0 (0%) | 2 (4.8%) | 0.079 |
| Beta-blockers | 88 (59%) | 65 (61%) | 23 (55%) | 0.464 |
| Aspirin | 84 (57%) | 63 (59%) | 21 (50%) | 0.296 |
| P2Y12 Inhibitors | 39 (26%) | 30 (28%) | 9 (21%) | 0.392 |
| Anticoagulants | 33 (22%) | 23 (22%) | 10 (24%) | 0.781 |
| Statins | 103 (70%) | 77 (73%) | 26 (62%) | 0.200 |
| Calcium-channel Blockers | 36 (24%) | 25 (24%) | 11 (26%) | 0.739 |
| Loop Diuretics | 70 (47%) | 50 (47%) | 20 (48%) | 0.961 |
| Loop Diuretics Dose (daily) | 46 (51) | 36 (25) | 69 (83) | 0.077 |
| Thiazide Diuretics | 34 (23%) | 25 (24%) | 9 (21%) | 0.779 |
| Thiazide Dose (daily) | 0.718 | |||
| 2.5 | 2 (7.7%) | 1 (5.3%) | 1 (14%) | |
| 5 | 3 (12%) | 3 (16%) | 0 (0%) | |
| 12.5 | 14 (54%) | 10 (53%) | 4 (57%) | |
| 25 | 5 (19%) | 4 (21%) | 1 (14%) | |
| 50 | 2 (7.7%) | 1 (5.3%) | 1 (14%) | |
| Potassium-sparing Diuretics | 13 (8.8%) | 9 (8.5%) | 4 (9.5%) | >0.999 |
| MRA Dose (daily) | 0.055 | |||
| 25 | 1 (9.1%) | 0 (0%) | 1 (33%) | |
| 50 | 9 (82%) | 8 (100%) | 1 (33%) | |
| 100 | 1 (9.1%) | 0 (0%) | 1 (33%) | |
| Gastroprotective Therapy | 103 (70%) | 77 (73%) | 26 (62%) | 0.172 |
| Insulin Therapy | 17 (11%) | 11 (10%) | 6 (14%) | 0.569 |
| Oral Hypoglycemic Agents | 48 (32%) | 36 (34%) | 12 (29%) | 0.528 |
| Sinus Rhythm | 109 (84%) | 78 (84%) | 31 (86%) | 0.753 |
| Heart Rate (bpm) | 71 (13) | 71 (13) | 71 (11) | 0.805 |
| Atrial Fibrillation | 18 (15%) | 13 (15%) | 5 (14%) | 0.926 |
| First-degree AV Block | 17 (16%) | 9 (12%) | 8 (29%) | 0.067 |
| Left Bundle Branch Block | 11 (10%) | 8 (10%) | 3 (11%) | >0.999 |
| Right Bundle Branch Block | 18 (17%) | 14 (18%) | 4 (14%) | 0.775 |
| T Wave Abnormalities | 40 (37%) | 32 (41%) | 8 (28%) | 0.202 |
| EuroSCORE II | 3.57 (2.29 - 4.62) | 3.73 (2.38 - 4.91) | 2.52 (2.10 - 4.61) | 0.173 |
| STS Mortality Risk | 6 (4 - 10) | 7 (4 - 10) | 6 (3 - 8) | 0.482 |
| Serum Creatinine (Pre-procedure) | 1.07 (0.53) | 1.08 (0.56) | 1.04 (0.43) | 0.756 |
| Creatinine Clearance (Pre-procedure) | 51 (25) | 50 (24) | 58 (27) | 0.389 |
| Hemoglobin (Pre-procedure) | 11.95 (1.90) | 11.70 (1.91) | 12.55 (1.76) | 0.021 |
| Hematocrit (Pre-procedure) | 35.7 (5.4) | 35.1 (5.5) | 37.3 (4.9) | 0.031 |
| Right Coronary Artery (RCA) Disease | 10 (9.0%) | 10 (12%) | 0 (0%) | 0.115 |
| Left Anterior Descending (LAD) Disease | 24 (22%) | 19 (23%) | 5 (19%) | 0.715 |
| Circumflex (CX) Disease | 9 (8.2%) | 6 (7.1%) | 3 (12%) | 0.439 |
| Concomitant PCI | 11 (9.2%) | 9 (10%) | 2 (5.9%) | 0.726 |
| Renal Guard Protocol | 3 (2.9%) | 1 (1.3%) | 2 (6.7%) | 0.196 |
| Additional Device | 0.732 | |||
| 0 | 26 (90%) | 12 (86%) | 14 (93%) | |
| 1 | 1 (3.4%) | 1 (7.1%) | 0 (0%) | |
| 2 | 2 (6.9%) | 1 (7.1%) | 1 (6.7%) | |
| Evolut R 23 mm | 10 (7.4%) | 9 (9.6%) | 1 (2.4%) | 0.174 |
| Evolut R 26 mm | 45 (33%) | 30 (32%) | 15 (36%) | 0.664 |
| Evolut R 29 mm | 39 (29%) | 34 (36%) | 5 (12%) | 0.004 |
| Evolut R 34 mm | 13 (9.6%) | 5 (5.3%) | 8 (19%) | 0.023 |
| Evolut PRO 23 mm | 3 (2.2%) | 1 (1.1%) | 2 (4.8%) | 0.225 |
| Evolut PRO 26 mm | 4 (2.9%) | 4 (4.3%) | 0 (0%) | 0.311 |
| Evolut PRO 29 mm | 3 (2.2%) | 0 (0%) | 3 (7.1%) | 0.028 |
| Evolut PRO 34 mm | 1 (0.7%) | 0 (0%) | 1 (2.4%) | 0.309 |
| Evolut ProPlus 26 mm | 1 (0.7%) | 0 (0%) | 1 (2.4%) | 0.311 |
| Evolut ProPlus 29 mm | 1 (0.7%) | 0 (0%) | 1 (2.4%) | 0.309 |
| MyVal 21.5 mm | 3 (2.2%) | 1 (1.1%) | 2 (4.8%) | 0.225 |
| MyVal 23 mm | 4 (2.9%) | 3 (3.2%) | 1 (2.4%) | >0.999 |
| MyVal 24.5 mm | 3 (2.2%) | 2 (2.1%) | 1 (2.4%) | >0.999 |
| Allegra 27 mm | 4 (2.9%) | 4 (4.3%) | 0 (0%) | 0.311 |
| Evolut FX 34 mm | 2 (1.5%) | 1 (1.1%) | 1 (2.4%) | 0.524 |
| Pre-procedural Femoral PTA | ||||
| 0 | 134 (100%) | 95 (100%) | 39 (100%) | |
| Anticoagulation | 3 (15%) | 2 (18%) | 1 (11%) | >0.999 |
| Transfemoral Access | 130 (99%) | 91 (99%) | 39 (100%) | >0.999 |
| Transapical Access | 1 (0.8%) | 1 (1.1%) | 0 (0%) | >0.999 |
| TEE-guided Procedure | ||||
| 0 | 52 (100%) | 30 (100%) | 22 (100%) | |
| Intraprocedural Complications | 33 (32%) | 19 (27%) | 14 (45%) | 0.068 |
| Optimal Valve Implantation | 93 (97%) | 66 (97%) | 27 (96%) | >0.999 |
| High Implantation | ||||
| 0 | 74 (100%) | 57 (100%) | 17 (100%) | |
| Low Implantation | 1 (1.4%) | 1 (1.8%) | 0 (0%) | >0.999 |
| Failed Implantation | 1 (1.0%) | 0 (0%) | 1 (3.3%) | 0.306 |
| Post-dilation | ||||
| 0 | 90 (100%) | 64 (100%) | 26 (100%) | |
| Valve-in-Valve Procedure | 11 (8.1%) | 10 (10%) | 1 (2.5%) | 0.174 |
| Coronary Ostium Occlusion | ||||
| 0 | 102 (100%) | 72 (100%) | 30 (100%) | |
| Residual Aortic Insufficiency (Angiographic) | 0.727 | |||
| 0 | 90 (94%) | 65 (94%) | 25 (93%) | |
| 1 | 5 (5.2%) | 3 (4.3%) | 2 (7.4%) | |
| 2 | 1 (1.0%) | 1 (1.4%) | 0 (0%) | |
| Prolonged Hypotension | 1 (0.9%) | 0 (0%) | 1 (3.1%) | 0.294 |
| Cardiopulmonary Resuscitation | ||||
| 0 | 112 (100%) | 79 (100%) | 33 (100%) | |
| Pulmonary Edema | 1 (0.9%) | 1 (1.3%) | 0 (0%) | >0.999 |
| Cardiac Tamponade | ||||
| 0 | 112 (100%) | 79 (100%) | 33 (100%) | |
| Intra-aortic Balloon Pump | ||||
| 0 | 112 (100%) | 79 (100%) | 33 (100%) | |
| Cardiogenic Shock | ||||
| 0 | 112 (100%) | 79 (100%) | 33 (100%) | |
| Stroke (Intra-procedural) | 1 (0.9%) | 1 (1.3%) | 0 (0%) | >0.999 |
| Transient Ischemic Attack (Intra-procedural) | ||||
| 0 | 112 (100%) | 79 (100%) | 33 (100%) | |
| New Onset Bundle Branch Block | 13 (12%) | 7 (8.8%) | 6 (18%) | 0.196 |
| First-degree AV Block (Intra-procedural) | 1 (0.9%) | 0 (0%) | 1 (3.1%) | 0.291 |
| Second-degree AV Block (Intra-procedural) | ||||
| 0 | 110 (100%) | 79 (100%) | 31 (100%) | |
| Advanced AV Block (Intra-procedural) | 8 (7.2%) | 4 (5.1%) | 4 (13%) | 0.224 |
| Atrial Fibrillation (Intra-procedural) | 1 (0.9%) | 1 (1.3%) | 0 (0%) | >0.999 |
| Ventricular Fibrillation | ||||
| 0 | 112 (100%) | 79 (100%) | 33 (100%) | |
| Ventricular Tachycardia | 1 (0.9%) | 1 (1.3%) | 0 (0%) | >0.999 |
| Bleeding | 2 (1.8%) | 1 (1.3%) | 1 (3.1%) | 0.492 |
| Femoral Occlusion | 2 (1.8%) | 2 (2.5%) | 0 (0%) | >0.999 |
| Femoral Artery Dissection | 3 (2.7%) | 3 (3.8%) | 0 (0%) | 0.557 |
| Residual Stenosis >70% | ||||
| 0 | 111 (100%) | 79 (100%) | 32 (100%) | |
| Vascular Surgery Required | ||||
| 0 | 111 (100%) | 79 (100%) | 32 (100%) | |
| Femoral Stent Placement | 4 (3.6%) | 3 (3.8%) | 1 (3.1%) | >0.999 |
| Femoral Balloon Angioplasty | 3 (2.7%) | 1 (1.3%) | 2 (6.5%) | 0.191 |
| Embolism | 1 (0.9%) | 1 (1.3%) | 0 (0%) | >0.999 |
| Transfusions | 1 (0.9%) | 1 (1.3%) | 0 (0%) | >0.999 |
| Number of Blood Units | 1 (0.9%) | 1 (1.3%) | 0 (0%) | >0.999 |
| Periprocedural MI | ||||
| 0 | 112 (100%) | 80 (100%) | 32 (100%) | |
| Intubation | 2 (1.8%) | 2 (2.5%) | 0 (0%) | >0.999 |
| Conversion to Cardiac Surgery | ||||
| 0 | 112 (100%) | 80 (100%) | 32 (100%) | |
| Intra-procedural Death | ||||
| 0 | 136 (100%) | 97 (100%) | 39 (100%) | |
| Serum Creatinine (Post-procedure Peak) | 1.00 (0.80 - 1.40) | 1.00 (0.80 - 1.40) | 1.00 (0.80 - 1.30) | 0.417 |
| Delta Creatinine | 0.10 (0.00 - 0.20) | 0.10 (0.00 - 0.20) | 0.00 (-0.10 - 0.20) | 0.530 |
| Percentage Change in Creatinine | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| Acute Kidney Injury | 14 (9.9%) | 11 (11%) | 3 (7.5%) | 0.757 |
| Creatinine Clearance (Post-procedure Peak) | 47 (27) | 46 (26) | 60 (36) | 0.339 |
| Nadir Hemoglobin | 9.83 (1.64) | 9.64 (1.54) | 10.30 (1.79) | 0.045 |
| Nadir Hematocrit | 29.3 (4.8) | 28.7 (4.7) | 30.6 (4.9) | 0.042 |
| Creatinine at 24h | 1.07 (0.41) | 1.07 (0.40) | 1.07 (0.44) | 0.945 |
| Creatinine at 72h | 1.13 (0.66) | 1.14 (0.71) | 1.09 (0.57) | 0.913 |
| Creatinine Reduction | 1.08 (0.60) | 1.10 (0.64) | 1.05 (0.47) | 0.762 |
| Clearance Improvement | 51 (26) | 50 (26) | 57 (26) | 0.463 |
| Hemoglobin Reduction | 10.28 (1.39) | 10.15 (1.31) | 10.59 (1.56) | 0.092 |
| Hematocrit Reduction | 30.7 (4.0) | 30.4 (3.9) | 31.4 (4.4) | 0.216 |
| Drop in Hemoglobin | -2.20 (-3.10 - -1.30) | -2.20 (-3.00 - -1.30) | -2.10 (-3.20 - -1.30) | 0.963 |
| Death at Follow-up | 23 (22%) | 18 (22%) | 5 (21%) | 0.885 |
| Major Stroke at Follow-up | 2 (67%) | 2 (100%) | 0 (0%) | 0.333 |
| Minor Stroke at Follow-up | 1 (1.2%) | 1 (1.5%) | 0 (0%) | >0.999 |
| TIA at Follow-up | 1 (1.2%) | 0 (0%) | 1 (6.3%) | 0.193 |
| MI at Follow-up | 2 (2.4%) | 2 (2.9%) | 0 (0%) | >0.999 |
| New Pacemaker at Follow-up | 23 (26%) | 16 (23%) | 7 (37%) | 0.244 |
| Bleeding at Follow-up | 35 (38%) | 23 (33%) | 12 (57%) | 0.045 |
| Heart Failure at Follow-up | 6 (7.1%) | 6 (8.6%) | 0 (0%) | 0.585 |
| 1 n (%); Mean (SD); Median (Q1 - Q3) | ||||
| 2 Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test | ||||
TAVI
Table Proglide vs Manta vs Ch
Regressione per morte ed endpoint composito
Call:
coxph(formula = Surv(FU_Composite_timing, FU_Composite_Endpoint) ~
EMODINAMICA_Chiusura_accesso, data = df)
n= 136, number of events= 56
(15 osservazioni eliminate a causa di valori mancanti)
coef exp(coef) se(coef) z Pr(>|z|)
EMODINAMICA_Chiusura_accessoManta 0.1684 1.1834 0.3033 0.555 0.579
exp(coef) exp(-coef) lower .95 upper .95
EMODINAMICA_Chiusura_accessoManta 1.183 0.845 0.6531 2.144
Concordance= 0.525 (se = 0.032 )
Likelihood ratio test= 0.3 on 1 df, p=0.6
Wald test = 0.31 on 1 df, p=0.6
Score (logrank) test = 0.31 on 1 df, p=0.6Call:
coxph(formula = Surv(FU_Composite_timing, FU_Composite_Endpoint) ~
EMODINAMICA_Chiusura_accesso + BASELINE_ETA + `BASELINE_Euroscore II` +
LABORATORIO_Creatinina_Pre, data = df)
n= 51, number of events= 22
(100 osservazioni eliminate a causa di valori mancanti)
coef exp(coef) se(coef) z Pr(>|z|)
EMODINAMICA_Chiusura_accessoManta 0.048183 1.049363 0.561986 0.086 0.932
BASELINE_ETA 0.002597 1.002601 0.039511 0.066 0.948
`BASELINE_Euroscore II` -0.121203 0.885854 0.106134 -1.142 0.253
LABORATORIO_Creatinina_Pre 0.328849 1.389369 0.218676 1.504 0.133
exp(coef) exp(-coef) lower .95 upper .95
EMODINAMICA_Chiusura_accessoManta 1.0494 0.9530 0.3488 3.157
BASELINE_ETA 1.0026 0.9974 0.9279 1.083
`BASELINE_Euroscore II` 0.8859 1.1289 0.7195 1.091
LABORATORIO_Creatinina_Pre 1.3894 0.7198 0.9051 2.133
Concordance= 0.614 (se = 0.052 )
Likelihood ratio test= 2.61 on 4 df, p=0.6
Wald test = 2.99 on 4 df, p=0.6
Score (logrank) test = 3.17 on 4 df, p=0.5
Call:
coxph(formula = Surv(Deathdays, COMPLICANZE_death_fu) ~ EMODINAMICA_Chiusura_accesso,
data = df)
n= 105, number of events= 23
(46 osservazioni eliminate a causa di valori mancanti)
coef exp(coef) se(coef) z
EMODINAMICA_Chiusura_accessoManta -0.02111 0.97911 0.50926 -0.041
EMODINAMICA_Chiusura_accessoChirurgia NA NA 0.00000 NA
Pr(>|z|)
EMODINAMICA_Chiusura_accessoManta 0.967
EMODINAMICA_Chiusura_accessoChirurgia NA
exp(coef) exp(-coef) lower .95 upper .95
EMODINAMICA_Chiusura_accessoManta 0.9791 1.021 0.3609 2.657
EMODINAMICA_Chiusura_accessoChirurgia NA NA NA NA
Concordance= 0.5 (se = 0.045 )
Likelihood ratio test= 0 on 1 df, p=1
Wald test = 0 on 1 df, p=1
Score (logrank) test = 0 on 1 df, p=1Call:
coxph(formula = Surv(Deathdays, COMPLICANZE_death_fu) ~ EMODINAMICA_Chiusura_accesso +
BASELINE_ETA + `BASELINE_Euroscore II` + LABORATORIO_Creatinina_Pre,
data = df)
n= 40, number of events= 12
(111 osservazioni eliminate a causa di valori mancanti)
coef exp(coef) se(coef) z
EMODINAMICA_Chiusura_accessoManta -0.91047 0.40234 1.06189 -0.857
EMODINAMICA_Chiusura_accessoChirurgia NA NA 0.00000 NA
BASELINE_ETA -0.01289 0.98720 0.05059 -0.255
`BASELINE_Euroscore II` -0.07956 0.92352 0.09700 -0.820
LABORATORIO_Creatinina_Pre 0.58905 1.80228 0.25039 2.353
Pr(>|z|)
EMODINAMICA_Chiusura_accessoManta 0.3912
EMODINAMICA_Chiusura_accessoChirurgia NA
BASELINE_ETA 0.7989
`BASELINE_Euroscore II` 0.4121
LABORATORIO_Creatinina_Pre 0.0186 *
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
exp(coef) exp(-coef) lower .95 upper .95
EMODINAMICA_Chiusura_accessoManta 0.4023 2.4855 0.0502 3.225
EMODINAMICA_Chiusura_accessoChirurgia NA NA NA NA
BASELINE_ETA 0.9872 1.0130 0.8940 1.090
`BASELINE_Euroscore II` 0.9235 1.0828 0.7636 1.117
LABORATORIO_Creatinina_Pre 1.8023 0.5549 1.1033 2.944
Concordance= 0.685 (se = 0.097 )
Likelihood ratio test= 5.04 on 4 df, p=0.3
Wald test = 6.65 on 4 df, p=0.2
Score (logrank) test = 8.33 on 4 df, p=0.08
Forest
| Characteristic |
Composite Endpoint
|
Death FU
|
||||
|---|---|---|---|---|---|---|
| HR1 | 95% CI1 | p-value | HR1 | 95% CI1 | p-value | |
| Closure Type | ||||||
| Proglide | — | — | — | — | ||
| Manta | 1.05 | 0.35, 3.16 | >0.9 | 0.40 | 0.05, 3.22 | 0.4 |
| Chirurgia | ||||||
| BASELINE_ETA | 1.00 | 0.93, 1.08 | >0.9 | 0.99 | 0.89, 1.09 | 0.8 |
| BASELINE_Euroscore II | 0.89 | 0.72, 1.09 | 0.3 | 0.92 | 0.76, 1.12 | 0.4 |
| LABORATORIO_Creatinina_Pre | 1.39 | 0.91, 2.13 | 0.13 | 1.80 | 1.10, 2.94 | 0.019 |
| 1 HR = Hazard Ratio, CI = Confidence Interval | ||||||